Durvalumab activity in previously treated patients who stopped durvalumab without disease progression by Jean-Charles Soria, Ashok Gupta, Siddharth Sheth, Chen Gao, Nancy Mueller, Natasha Angra, Caroline Germa, Pablo Martinez

Get full text

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types by Patricia Martin‐Romano, Eduardo Castanon, Samy Ammari, Stéphane Champiat, Antoine Hollebecque, Sophie Postel‐Vinay, Capucine Baldini, Andrea Varga, Jean Marie Michot, Perrine Vuagnat, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté, Christophe Massard

Get full text

Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience by Claudia Parisi, José Carlos Benitez, Hélène Lecourt, Filippo Gustavo dall’Olio, Mihaela Aldea, Felix Blanc-Durand, Véronique Vergé, Cyril Quivoron, Charles Naltet, Pamela Abdayem, Pernelle Lavaud, Maria Rosa Ghigna, Luc Friboulet, Yohann Loriot, Stéphane De Botton, Vincent Ribrag, Andrea Ardizzoni, David Planchard, Jean-Charles Soria, Fabrice Barlesi, Benjamin Besse

Get full text

Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells by Jean-Charles Soria, Charles Ferte, Christophe Massard, Roger Sun, Guillaume Louvel, Eric Deutsch, Benjamin Frey, Markus Hecht, Rainer Fietkau, Nora Sundahl, Florian Putz, Andrea Lancia, Angela Rouyar, Marina Milic, Alexandre Carré, Enzo Battistella, Emilie Alvarez Andres, Stéphane Niyoteka, Edouard Romano, Jérôme Durand-Labrunie, Sophie Bockel, Rastilav Bahleda, Charlotte Robert, Celine Boutros, Maria Vakalopoulou, Nikos Paragios, Piet Ost, Udo Gaipl

Get full text